Corresponding Author: Karina W. Davidson, PhD, MASc, Feinstein Institutes for Medical Research, 130 E 59th St, Ste 14C, New York, NY 10032(chair@uspstf.net)
Accepted for Publication: July 20, 2021.
Correction: This article was corrected on October 26, 2021, to fix an unclear diagnostic testing standard in the Practice Considerations section.
The US Preventive Services Task Force (USPSTF) members: Karina W. Davidson, PhD, MASc; Michael J. Barry, MD; Carol M. Mangione, MD, MSPH; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; Alex H. Krist, MD, MPH; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Douglas K. Owens, MD, MS; Lori Pbert, PhD; Michael Silverstein, MD, MPH; James Stevermer, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) members: Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York (Davidson); Harvard Medical School, Boston, Massachusetts (Barry); University of California, Los Angeles (Mangione); Albert Einstein College of Medicine, New York, New York (Cabana); Oregon Health & Science University, Portland (Caughey); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); University of North Carolina at Chapel Hill (Donahue); Mayo Clinic, Rochester, Minnesota (Doubeni); Fairfax Family Practice Residency, Fairfax, Virginia (Krist); Virginia Commonwealth University, Richmond (Krist); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); Stanford University, Stanford, California (Owens); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); University of Missouri, Columbia (Stevermer); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).
Author Contributions: Dr Davidson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Howard Tracer, MD (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
Additional Information: The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
2.Jonas
D , Crotty
K , Yun
JD ,
et al. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 207. Agency for Healthcare Research and Quality; 2021. AHRQ publication 21-05276-EF-1.
3.Glauber
H , Vollmer
WM , Nichols
GA . A simple model for predicting two-year risk of diabetes development in individuals with prediabetes.
Perm J. 2018;22:17-050.
PubMedGoogle Scholar 5.Portillo-Sanchez
P , Bril
F , Maximos
M ,
et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.
J Clin Endocrinol Metab. 2015;100(6):2231-2238. doi:
10.1210/jc.2015-1966PubMedGoogle ScholarCrossref 9.Rubin
KH , Glintborg
D , Nybo
M , Abrahamsen
B , Andersen
M . Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 2017;102(10):3848-3857. doi:
10.1210/jc.2017-01354PubMedGoogle ScholarCrossref 12.Lee
JW , Brancati
FL , Yeh
HC . Trends in the prevalence of type 2 diabetes in Asians versus Whites: results from the United States National Health Interview Survey, 1997-2008.
Diabetes Care. 2011;34(2):353-357. doi:
10.2337/dc10-0746PubMedGoogle ScholarCrossref 17.Herman
WH , Ye
W , Griffin
SJ ,
et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe).
Diabetes Care. 2015;38(8):1449-1455. doi:
10.2337/dc14-2459PubMedGoogle ScholarCrossref 18.Knowler
WC , Barrett-Connor
E , Fowler
SE ,
et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med. 2002;346(6):393-403. doi:
10.1056/NEJMoa012512PubMedGoogle Scholar 19.Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Diabetes Care. 2019;42(4):601-608. doi:
10.2337/dc18-1970PubMedGoogle ScholarCrossref 20.Curry
SJ , Krist
AH , Owens
DK ,
et al; US Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement.
JAMA. 2018;320(11):1163-1171. doi:
10.1001/jama.2018.13022PubMedGoogle Scholar 21.Siu
AL ; US Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med. 2015;163(11):861-868. doi:
10.7326/M15-2345PubMedGoogle ScholarCrossref 23.Jonas
DE , Crotty
K , Yun
JD ,
et al. Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA. Published August 24, 2021. doi:
10.1001/jama.2021.10403Google Scholar 24.Echouffo-Tcheugui
JB , Simmons
RK , Williams
KM ,
et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.
BMC Public Health. 2009;9:136. doi:
10.1186/1471-2458-9-136PubMedGoogle ScholarCrossref 26.Echouffo-Tcheugui
JB , Simmons
RK , Prevost
AT ,
et al. Long-term effect of population screening for diabetes on cardiovascular morbidity, self-rated health, and health behavior.
Ann Fam Med. 2015;13(2):149-157. doi:
10.1370/afm.1737PubMedGoogle ScholarCrossref 28.Rahman
M , Simmons
RK , Hennings
SH , Wareham
NJ , Griffin
SJ . How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? twelve year follow-up of the Ely cohort.
Diabetologia. 2012;55(6):1651-1659. doi:
10.1007/s00125-011-2441-9PubMedGoogle ScholarCrossref 29.Rahman
M , Simmons
RK , Hennings
SH , Wareham
NJ , Griffin
SJ . Effect of screening for type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort.
Diabet Med. 2012;29(7):886-892. doi:
10.1111/j.1464-5491.2012.03570.xPubMedGoogle ScholarCrossref 30.Griffin
SJ , Borch-Johnsen
K , Davies
MJ ,
et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
Lancet. 2011;378(9786):156-167. doi:
10.1016/S0140-6736(11)60698-3PubMedGoogle ScholarCrossref 31.Simmons
RK , Sharp
SJ , Sandbæk
A ,
et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? findings from the ADDITION-Europe cluster-randomized trial.
Diabet Med. 2012;29(11):e409-e416. doi:
10.1111/j.1464-5491.2012.03759.xPubMedGoogle ScholarCrossref 32.Simmons
RK , Borch-Johnsen
K , Lauritzen
T ,
et al. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.
Health Technol Assess. 2016;20(64):1-86. doi:
10.3310/hta20640PubMedGoogle ScholarCrossref 33.Griffin
SJ , Rutten
GEHM , Khunti
K ,
et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.
Lancet Diabetes Endocrinol. 2019;7(12):925-937. doi:
10.1016/S2213-8587(19)30349-3PubMedGoogle ScholarCrossref 34.Li
G , Zhang
P , Wang
J ,
et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
Lancet Diabetes Endocrinol. 2014;2(6):474-480. doi:
10.1016/S2213-8587(14)70057-9PubMedGoogle ScholarCrossref 35.Gong
Q , Zhang
P , Wang
J ,
et al; Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.
Lancet Diabetes Endocrinol. 2019;7(6):452-461. doi:
10.1016/S2213-8587(19)30093-2PubMedGoogle ScholarCrossref 36.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet. 1998;352(9131):837-853. doi:
10.1016/S0140-6736(98)07019-6PubMedGoogle ScholarCrossref 39.Davies
MJ , Heller
S , Skinner
TC ,
et al; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial.
BMJ. 2008;336(7642):491-495. doi:
10.1136/bmj.39474.922025.BEPubMedGoogle ScholarCrossref 40.Khunti
K , Gray
LJ , Skinner
T ,
et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care.
BMJ. 2012;344:e2333. doi:
10.1136/bmj.e2333PubMedGoogle Scholar 41.Yang
Y , Yao
JJ , Du
JL ,
et al. Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese.
Diabetes Care. 2013;36(4):978-984. doi:
10.2337/dc12-0227PubMedGoogle ScholarCrossref 43.Ratner
R , Goldberg
R , Haffner
S ,
et al; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program.
Diabetes Care. 2005;28(4):888-894. doi:
10.2337/diacare.28.4.888PubMedGoogle Scholar 44.Park
P , Simmons
RK , Prevost
AT , Griffin
SJ . Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice.
BMC Public Health. 2008;8:350. doi:
10.1186/1471-2458-8-350PubMedGoogle ScholarCrossref 45.Eborall
HC , Griffin
SJ , Prevost
AT , Kinmonth
AL , French
DP , Sutton
S . Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial.
BMJ. 2007;335(7618):486. doi:
10.1136/bmj.39303.723449.55PubMedGoogle ScholarCrossref 46.Paddison
CA , Eborall
HC , French
DP ,
et al. Predictors of anxiety and depression among people attending diabetes screening: a prospective cohort study embedded in the ADDITION (Cambridge) randomized control trial.
Br J Health Psychol. 2011;16(pt 1):213-226. doi:
10.1348/135910710X495366PubMedGoogle Scholar 49.Handelsman
Y , Bloomgarden
ZT , Grunberger
G ,
et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015.
Endocr Pract. 2015;21(suppl 1):1-87. doi:
10.4158/EP15672.GLSUPPLPubMedGoogle ScholarCrossref